Loading...
Loading...
Also known as: Mounjaro, Zepbound, GIP/GLP-1 dual agonist
Dual GIP and GLP-1 receptor agonist that produces superior weight loss and glycemic control compared to GLP-1 agonists alone.
Benefits
6
Conditions
5
Evidence
SURPASS and SURMOUNT trials, FDA approved+ studies
Source
Synthetic dual GIP/GLP-1 receptor agonist
Gabriel Brain Score
Strong
Dual GIP and GLP-1 receptor agonist that produces superior weight loss and glycemic control compared to GLP-1 agonists alone.
Activates both GIP and GLP-1 receptors for synergistic metabolic effects, enhances insulin secretion while suppressing glucagon, reduces appetite via hypothalamic pathways, improves insulin sensitivity, promotes thermogenesis and energy expenditure.
* Dosing should be individualized. Always consult with a qualified healthcare practitioner.
SURPASS and SURMOUNT trials, FDA approved
SURMOUNT trials demonstrated 20-25% weight loss, superior to semaglutide. SURPASS trials showed excellent glycemic control. FDA approved for diabetes (Mounjaro) and obesity (Zepbound). Emerging as most effective pharmacological weight loss agent.
Investigational triple agonist targeting GIP, GLP-1, and glucagon receptors for maximal metabolic benefit and weight loss.
Long-acting GLP-1 receptor agonist that reduces appetite, improves glycemic control, and promotes significant weight loss.
Investigational dual glucagon and GLP-1 receptor agonist for obesity and metabolic dysfunction-associated steatohepatitis (MASH).